MedTrace Logo

Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial

NCT02699645 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1671

Last updated 2025-09-12

No results posted yet for this study

Summary

An investigator initiated and conducted, multicentre, international, double-blinded, placebo-controlled, parallel-group, randomised controlled trial to determine the effect of more intensive blood pressure control provided by a fixed low-dose combination blood pressure lowering pill ("Triple Pill") strategy on top of standard of care, on time to first occurrence of recurrent stroke in patients with a history of stroke due to intracerebral haemorrhage.

Conditions

Interventions

DRUG

telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg

1 pill taken orally once daily for average of 72 months

DRUG

Placebo

1 pill taken orally once daily for average of 72 months

Sponsors & Collaborators

  • The University of New South Wales

    collaborator OTHER

  • The George Institute

    lead OTHER

Principal Investigators

  • Craig Anderson · The George Institute

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-28
Primary Completion
2025-08-27
Completion
2025-08-27

Countries

  • Australia
  • Brazil
  • Georgia
  • Malaysia
  • Netherlands
  • Nigeria
  • Singapore
  • Sri Lanka
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02699645 on ClinicalTrials.gov